Ocular Therapeutix, Inc. $OCUL Shares Bought by Second Line Capital LLC

by · The Markets Daily

Second Line Capital LLC grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report) by 20.9% during the second quarter, HoldingsChannel.com reports. The fund owned 638,640 shares of the biopharmaceutical company’s stock after purchasing an additional 110,350 shares during the quarter. Ocular Therapeutix makes up about 1.1% of Second Line Capital LLC’s portfolio, making the stock its 18th biggest holding. Second Line Capital LLC’s holdings in Ocular Therapeutix were worth $6,271,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in OCUL. Steward Partners Investment Advisory LLC boosted its position in Ocular Therapeutix by 124.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,242 shares during the period. Rockefeller Capital Management L.P. purchased a new position in Ocular Therapeutix in the fourth quarter valued at about $31,000. Hilton Head Capital Partners LLC raised its position in Ocular Therapeutix by 30.4% in the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,053 shares during the period. Atlas Capital Advisors Inc. acquired a new position in shares of Ocular Therapeutix during the fourth quarter worth about $61,000. Finally, Caitong International Asset Management Co. Ltd lifted its stake in shares of Ocular Therapeutix by 420.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 6,412 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 5,179 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Insider Transactions at Ocular Therapeutix

In other news, insider Jeffrey Heier sold 3,296 shares of the stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $10.78, for a total transaction of $35,530.88. Following the transaction, the insider owned 318,326 shares of the company’s stock, valued at approximately $3,431,554.28. This trade represents a 1.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Pravin Dugel sold 21,649 shares of Ocular Therapeutix stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $10.77, for a total value of $233,159.73. Following the completion of the transaction, the insider owned 2,525,429 shares of the company’s stock, valued at $27,198,870.33. This trade represents a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 29,877 shares of company stock valued at $321,827. Insiders own 3.10% of the company’s stock.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $10.64 on Tuesday. The firm has a market cap of $2.34 billion, a price-to-earnings ratio of -7.49 and a beta of 0.97. The company has a quick ratio of 13.03, a current ratio of 13.10 and a debt-to-equity ratio of 0.14. The business’s 50 day moving average is $9.77 and its two-hundred day moving average is $9.25. Ocular Therapeutix, Inc. has a 52-week low of $6.23 and a 52-week high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.05. The company had revenue of $13.47 million during the quarter, compared to analyst estimates of $13.20 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The firm’s revenue for the quarter was down .1% compared to the same quarter last year. During the same period last year, the business earned ($0.39) EPS. Analysts forecast that Ocular Therapeutix, Inc. will post -1.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on OCUL. Chardan Capital reiterated a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research note on Tuesday, August 4th. Robert W. Baird boosted their price target on Ocular Therapeutix from $24.00 to $30.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Wall Street Zen upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective (up from $21.00) on shares of Ocular Therapeutix in a research note on Thursday, June 18th. Eleven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $25.75.

Check Out Our Latest Stock Report on OCUL

Ocular Therapeutix Company Profile

(Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

Recommended Stories

Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix, Inc. (NASDAQ:OCUL – Free Report).